Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug | Zendy

Laurent Lemaire | Zendy; Malet-Martino Mc | Zendy; M Forni | Zendy; Robert Martino | Zendy; Bruno Lasserre | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug

Author(s) -

Laurent Lemaire,

Malet-Martino Mc,

M Forni,

Robert Martino,

Bruno Lasserre

Publication year - 1992

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/bjc.1992.227

Subject(s) - cardiotoxicity , vial , fluorouracil , fluoroacetate , chemistry , drug , pharmacology , hydrolysis , chromatography , impurity , toxicity , chemotherapy , medicine , biochemistry , surgery , organic chemistry

The cardiotoxicity of 5-fluorouracil (FU) was attributed to impurities present in the injected vials. One of these impurities was identified as fluoroacetaldehyde which is metabolised by isolated perfused rabbit hearts into fluoroacetate (FAC), a highly cardiotoxic compound. FAC was also detected in the urine of patients treated with FU. These impurities were found to be degradation products of FU that are formed in the basic medium employed to dissolve this compound. To avoid chemical degradation of this antineoplastic drug, the solution of FU that will be injected should be prepared immediately before use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research